Bivatuzumab Biosimilar - Research Grade

Human

CD44

>1mg/ml

IgG1 - kappa

CHO Cells

Anti-Mouse CD44 (IM7) In Vivo Antibody - Low Endotoxin (ICH1115)

https://www.imgt.org/mAb-DB/

ICH3002

P16070

960

Blue ice

This product is a research-grade biosimilar of bivatuzumab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is not a clinical drug and carries none of the payloads associated with the originator program. Bivatuzumab is a humanized IgG1 antibody built around CD44, and more specifically the v6 variant epitope of the CD44 adhesion receptor. The originator was developed as a tumor-targeting agent and was best known in its mertansine-conjugated form (bivatuzumab mertansine) evaluated in head and neck and esophageal squamous cell carcinoma; that program was discontinued after dose-limiting skin toxicity linked to CD44v6 expression on keratinocytes. This ichor.bio material reproduces the antigen-binding specificity of the originator in an unconjugated format so investigators can study CD44/CD44v6 engagement without therapeutic intent. It is manufactured to research-grade low-endotoxin standards (<1 EU/mg) and is available in bulk milligram to gram quantities, making it suitable as a binding reagent, assay control, or benchmarking tool in target-biology and antibody-characterization workflows. Guidance is provided for ichor.bio to review. CD44 (UniProt P16070) is a widely expressed type I transmembrane glycoprotein that serves as the principal cell-surface receptor for hyaluronan and also engages osteopontin, collagens, and matrix metalloproteinases. Through these interactions it mediates cell-cell and cell-matrix adhesion, migration, and signaling. The CD44 gene undergoes extensive alternative splicing of variable exons, generating variant isoforms; the v6-containing isoforms (CD44v6) are of particular interest because they are enriched in several epithelial carcinomas and have been implicated in tumor invasion, metastasis, and receptor tyrosine kinase co-signaling. Bivatuzumab is directed against the CD44v6 epitope rather than the standard isoform, giving it selectivity for variant-expressing cells. Because CD44v6 is also present on normal squamous keratinocytes, on-target binding in skin was a key finding in originator studies.

CDw44, Epican, Extracellular matrix receptor III, ECMR-III, GP90 lymphocyte homing/adhesion receptor, HUTCH-I, Heparan sulfate proteoglycan, Hermes antigen, Hyaluronate receptor, Phagocytic glycoprotein 1, PGP-1, Phagocytic glycoprotein I, PGP-I, CD44 ant

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Bivatuzumab (anti-CD44) Biosimilar

Q: Is the Bivatuzumab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Bivatuzumab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Bivatuzumab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Bivatuzumab that binds CD44; for research use only.